Virtus ETF Advisers’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $487K | Buy |
27,098
+1,298
| +5% | +$24.6K | 0.19% | 140 |
|
|
2026
Q1 | $561K | Hold |
25,800
| – | – | 0.26% | 105 |
|
|
2025
Q4 | $555K | Hold |
25,800
| – | – | 0.26% | 98 |
|
|
2025
Q3 | $497K | Buy |
+25,800
| New | +$460K | 0.27% | 106 |
|
|
2025
Q1 | – | Sell |
-2,809
| Closed | -$342K | – | 752 |
|
|
2024
Q4 | $342K | Buy |
2,809
+174
| +7% | +$21.3K | 0.14% | 212 |
|
|
2024
Q3 | $329K | Hold |
2,635
| – | – | 0.15% | 223 |
|
|
2024
Q2 | $416K | Sell |
2,635
-1,396
| -35% | -$179K | 0.2% | 184 |
|
|
2024
Q1 | $522K | Buy |
4,031
+580
| +17% | +$71K | 0.28% | 178 |
|
|
2023
Q4 | $333K | Buy |
3,451
+1,117
| +48% | +$107K | 0.21% | 203 |
|
|
2023
Q3 | $283K | Sell |
2,334
-301
| -11% | -$34K | 0.17% | 207 |
|
|
2023
Q2 | $302K | Buy |
2,635
+198
| +8% | +$25.5K | 0.18% | 206 |
|
|
2023
Q1 | $336K | Buy |
2,437
+42
| +2% | +$5.45K | 0.18% | 172 |
|
|
2022
Q4 | $310K | Sell |
2,395
-1,258
| -34% | -$146K | 0.16% | 249 |
|
|
2022
Q3 | $404K | Buy |
3,653
+57
| +2% | +$5.75K | 0.16% | 229 |
|
|
2022
Q2 | $270K | Sell |
3,596
-749
| -17% | -$55.1K | 0.1% | 281 |
|
|
2022
Q1 | $339K | Hold |
4,345
| – | – | 0.15% | 164 |
|
|
2021
Q4 | $391K | Sell |
4,345
-966
| -18% | -$82.6K | 0.15% | 158 |
|
|
2021
Q3 | $491K | Sell |
5,311
-487
| -8% | -$37.5K | 0.22% | 140 |
|
|
2021
Q2 | $451K | Buy |
5,798
+2,112
| +57% | +$160K | 0.19% | 181 |
|
|
2021
Q1 | $275K | Buy |
3,686
+96
| +3% | +$8.86K | 0.12% | 261 |
|
|
2020
Q4 | $612K | Sell |
3,590
-89
| -2% | -$13.2K | 0.25% | 105 |
|
|
2020
Q3 | $517K | Buy |
3,679
+310
| +9% | +$47.1K | 0.27% | 129 |
|
|
2020
Q2 | $540K | Sell |
3,369
-1,088
| -24% | -$148K | 0.26% | 141 |
|
|
2020
Q1 | $436K | Sell |
4,457
-376
| -8% | -$43K | 0.18% | 184 |
|
|
2019
Q4 | $624K | Sell |
4,833
-961
| -17% | -$97K | 0.1% | 183 |
|
|
2019
Q3 | $436K | Sell |
5,794
-976
| -14% | -$115K | 0.09% | 185 |
|
|
2019
Q2 | $1.03M | Buy |
+6,770
| New | +$823K | 0.22% | 150 |
|
|
2019
Q1 | – | Sell |
-4,976
| Closed | -$543K | – | 256 |
|
|
2018
Q4 | $543K | Sell |
4,976
-2,949
| -37% | -$369K | 0.09% | 73 |
|
|
2018
Q3 | $1.28M | Buy |
7,925
+534
| +7% | +$73K | 0.13% | 42 |
|
|
2018
Q2 | $977K | Sell |
7,391
-9,018
| -55% | -$850K | 0.86% | 10 |
|
|
2018
Q1 | $1.22M | Sell |
16,409
-1,488
| -8% | -$99.2K | 1.06% | 18 |
|
|
2017
Q4 | $996K | Sell |
17,897
-13,336
| -43% | -$706K | 1.25% | 18 |
|
|
2017
Q3 | $1.42M | Hold |
31,233
| – | – | 0.19% | 38 |
|
|
2017
Q2 | $1.05M | Sell |
31,233
-3,303
| -10% | -$108K | 0.16% | 59 |
|
|
2017
Q1 | $1.02M | Buy |
34,536
+3,321
| +11% | +$103K | 0.18% | 65 |
|
|
2016
Q4 | $856K | Buy |
31,215
+18,266
| +141% | +$734K | 0.26% | 77 |
|
|
2016
Q3 | $795K | Hold |
12,949
| – | – | 0.38% | 44 |
|
|
2016
Q2 | $247K | Buy |
12,949
+6,179
| +91% | +$114K | 0.18% | 91 |
|
|
2016
Q1 | $132K | Sell |
6,770
-433
| -6% | -$7.57K | 0.18% | 130 |
|
|
2015
Q4 | $278K | Buy |
+7,203
| New | +$234K | 0.76% | 47 |
|
Other funds holding SRPT
EAM
Virtus ETF Advisers's SRPT Position: Q2 2026 in Review
Virtus ETF Advisers increased its Sarepta Therapeutics (SRPT) stake by 5% in Q2 2026, buying an estimated $24.6K and bringing the position to 27,098 shares worth $487K. The position accounts for 0.19% of the portfolio, ranked #140.
Virtus ETF Advisers first reported a position in SRPT in Q4 2015 and has held it in 40 quarters since. The position peaked at $1.42M in Q3 2017. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Virtus ETF Advisers held 27,098 shares of Sarepta Therapeutics worth $487K as of Q2 2026.
- Virtus ETF Advisers bought 1,298 Sarepta Therapeutics shares in Q2 2026, an estimated $24.6K.
- Sarepta Therapeutics made up 0.19% of Virtus ETF Advisers's portfolio in Q2 2026, its #140 holding.
- Virtus ETF Advisers first reported a position in Sarepta Therapeutics in Q4 2015 and has held it in 40 quarters since.
- Virtus ETF Advisers's Sarepta Therapeutics position peaked at $1.42M in Q3 2017.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.